BR112022017305A2 - Moléculas de ligação ao antígenos multiespecíficas que têm como alvo claudina-6 e usos das mesmas - Google Patents

Moléculas de ligação ao antígenos multiespecíficas que têm como alvo claudina-6 e usos das mesmas

Info

Publication number
BR112022017305A2
BR112022017305A2 BR112022017305A BR112022017305A BR112022017305A2 BR 112022017305 A2 BR112022017305 A2 BR 112022017305A2 BR 112022017305 A BR112022017305 A BR 112022017305A BR 112022017305 A BR112022017305 A BR 112022017305A BR 112022017305 A2 BR112022017305 A2 BR 112022017305A2
Authority
BR
Brazil
Prior art keywords
cldn6
binding molecules
binding
specific antigen
molecules targeting
Prior art date
Application number
BR112022017305A
Other languages
English (en)
Portuguese (pt)
Inventor
Ishii Shinya
Kimura Naoki
Kodama Tatsushi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BR112022017305A2 publication Critical patent/BR112022017305A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112022017305A 2020-03-31 2021-03-30 Moléculas de ligação ao antígenos multiespecíficas que têm como alvo claudina-6 e usos das mesmas BR112022017305A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020062881 2020-03-31
JP2020073335 2020-04-16
PCT/JP2021/013526 WO2021200939A1 (en) 2020-03-31 2021-03-30 Claudin-6 targeting multispecific antigen-binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
BR112022017305A2 true BR112022017305A2 (pt) 2022-10-11

Family

ID=77928433

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017305A BR112022017305A2 (pt) 2020-03-31 2021-03-30 Moléculas de ligação ao antígenos multiespecíficas que têm como alvo claudina-6 e usos das mesmas

Country Status (18)

Country Link
US (1) US20230220066A1 (https=)
EP (1) EP4126956A4 (https=)
JP (2) JP6971419B2 (https=)
KR (2) KR102431028B1 (https=)
CN (1) CN115397855A (https=)
AU (1) AU2021247916A1 (https=)
BR (1) BR112022017305A2 (https=)
CA (1) CA3174094A1 (https=)
CL (2) CL2022002625A1 (https=)
CO (1) CO2022015202A2 (https=)
CR (2) CR20250119A (https=)
IL (1) IL296478A (https=)
MX (1) MX2022012092A (https=)
PE (1) PE20221760A1 (https=)
PH (1) PH12022552323A1 (https=)
SG (1) SG11202104264TA (https=)
TW (2) TWI900776B (https=)
WO (1) WO2021200939A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102813659B1 (ko) 2013-11-11 2025-05-28 추가이 세이야쿠 가부시키가이샤 개변된 항체 가변영역을 포함하는 항원 결합 분자
TWI831044B (zh) 2014-11-11 2024-02-01 日商中外製藥股份有限公司 抗原結合分子、包含抗原結合分子的醫藥組合物以及製造及選擇抗原結合分子之方法
TW201938194A (zh) 2017-12-05 2019-10-01 日商中外製藥股份有限公司 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
MX2022000111A (es) * 2019-07-10 2022-02-10 Chugai Pharmaceutical Co Ltd Moleculas de union a claudina-6 y usos de las mismas.
EP4395823A4 (en) * 2021-09-03 2025-07-16 Novarock Biotherapeutics Ltd BISPECIFIC BINDING PROTEINS THAT BIND TO CD137 AND A TUMOR-ASSOCIATED ANTIGEN
WO2023053282A1 (ja) * 2021-09-29 2023-04-06 中外製薬株式会社 がんの治療に用いるための細胞傷害誘導治療剤
KR20240133746A (ko) * 2022-01-09 2024-09-04 아이-맵 바이오파마 컴파니 리미티드 다중특이적 작제물 및 이의 용도
JP7730432B2 (ja) * 2022-10-19 2025-08-27 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
TW202430574A (zh) 2022-11-30 2024-08-01 美商積分分子股份有限公司 針對密連蛋白６之抗體，包括其雙特異性格式

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2241578B1 (en) 2008-01-11 2016-04-20 The University of Tokyo Anti-cldn6 antibody
DK3305813T3 (da) 2009-11-11 2020-04-20 Astellas Pharma Inc Antistoffer, der er specifikke for claudin 6 (cldn6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
ES2989943T3 (es) 2011-05-13 2024-11-28 Astellas Pharma Inc Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6
JP6499079B2 (ja) 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
RU2016122041A (ru) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
EP3568416A4 (en) * 2017-01-13 2020-07-08 Celdara Medical, LLC TIM-1 TARGETED CHIMERIC ANTIGENIC RECEPTORS
TW201938194A (zh) * 2017-12-05 2019-10-01 日商中外製藥股份有限公司 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
US20210054076A1 (en) * 2018-01-05 2021-02-25 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US12509524B2 (en) * 2018-09-28 2025-12-30 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region
MX2022000111A (es) * 2019-07-10 2022-02-10 Chugai Pharmaceutical Co Ltd Moleculas de union a claudina-6 y usos de las mismas.

Also Published As

Publication number Publication date
CO2022015202A2 (es) 2022-11-18
TWI900776B (zh) 2025-10-11
KR20220149774A (ko) 2022-11-08
SG11202104264TA (en) 2021-11-29
CN115397855A (zh) 2022-11-25
JP6971419B2 (ja) 2021-11-24
CR20250119A (es) 2025-06-26
MX2022012092A (es) 2022-10-13
TW202235442A (zh) 2022-09-16
KR102431028B1 (ko) 2022-08-10
PE20221760A1 (es) 2022-11-11
EP4126956A4 (en) 2024-04-24
IL296478A (en) 2022-11-01
KR20210143923A (ko) 2021-11-29
TWI770917B (zh) 2022-07-11
EP4126956A1 (en) 2023-02-08
CR20220540A (es) 2022-12-07
JP2022009816A (ja) 2022-01-14
PH12022552323A1 (en) 2023-12-04
CL2023002099A1 (es) 2023-12-22
WO2021200939A1 (en) 2021-10-07
CA3174094A1 (en) 2021-10-07
CL2022002625A1 (es) 2023-04-21
TW202204408A (zh) 2022-02-01
US20230220066A1 (en) 2023-07-13
AU2021247916A1 (en) 2022-10-20
JP2021168648A (ja) 2021-10-28

Similar Documents

Publication Publication Date Title
BR112022017305A2 (pt) Moléculas de ligação ao antígenos multiespecíficas que têm como alvo claudina-6 e usos das mesmas
CL2024003895A1 (es) Proteínas que se unen a nkg2d, flt3 y cd16; composición farmacéutica; y su uso.
CL2023002108A1 (es) Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.
AR122018A1 (es) Proteínas que se unen a nkg2d, cd16 y clec12a
CL2021002241A1 (es) Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
BR112022014522A2 (pt) Compostos degradadores, composição farmacêutica, métodos para tratar transtornos, compostos
CL2021000316A1 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
WO2020010250A3 (en) Anti-tcr antibody molecules and uses thereof
BR112021019471A2 (pt) Composições imunoterapêuticas e uso das mesmas
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
BR112023024209A2 (pt) Composições que compreendem um agente terapêutico de redirecionamento de células t e um agente terapêutico anti-cd44
BR112022005026A2 (pt) Conjugados terapêuticos
BR112021005722A2 (pt) moléculas de ligação ao antígeno capazes de ligar cd3 e cd137, porém não simultaneamente
BR112022024833A2 (pt) Conjugados anticorpo anti-bcma-fármaco e métodos de uso
BR112023002116A2 (pt) Proteínas que se ligam a nkg2d, cd16 e egfr
BR112022008756A2 (pt) Conjugados anticorpo-fármaco anti-mesotelina eribulina e métodos de uso
BR112022008552A2 (pt) Moléculas de ligação multiespecíficas de scfv de terminal-n
BR112019005685A2 (pt) células t com resistência à imunossupressão aumentada
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
BR112022006476A2 (pt) Oligonucleotídeos com análogos de nucleosídeos
CO2022016754A2 (es) Moléculas de fijación para el tratamiento de cáncer
BR112017016379A2 (pt) imunoconjugados, composição, uso de peptídeo, uso de imunoconjugado, método de geração de imunoconjugado e método de tratamento de pacientes
BR112023018832A2 (pt) Composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas
DOP2025000023A (es) Proteínas de unión a nkg2d, cd16 y ceacam5
AR121696A1 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos